Integragen (XPAR:ALINT) Total Receivables: €1.40 Mil (As of Jun. 2025)


XPAR:ALINT Integragen XPAR:ALINT
36 GF Score
Price €0.17
GF Value €0.42
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Integragen Total Receivables?

Integragen XPAR:ALINT -2.01% 36 Total Receivables is €1.40 Mil as of Jun. 2025. GuruFocus rates XPAR:ALINT with a GF Score™ of 36/100 and a GF Value™ of €0.42 (Possible Value Trap). The stock has 4 warning signs investors should review.

Integragen's Total Receivables for the quarter that ended in Jun. 2025 was €1.40 Mil.

Integragen Total Receivables Historical Data

* Premium members only.

The historical data trend for Integragen's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integragen Total Receivables Chart

Integragen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.67 3.49 4.30 1.67 1.41

Integragen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.30 3.48 1.67 1.40 1.41
XPAR:ALINT
36GF Score
Integragen XPAR:ALINT
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integragen Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €1.40 Mil mean?
Integragen (XPAR:ALINT) has a Total Receivables of €1.40 Mil as of Jun. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Integragen and its competitors.
Is Integragen's Total Receivables too high?
Integragen's current Total Receivables is €1.40 Mil. Overall, Integragen has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integragen's Total Receivables compare to VRTX and REGN?
Integragen's Total Receivables of €1.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Integragen and its competitors. Integragen's current Total Receivables is €1.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integragen stock overvalued right now?
Based on GuruFocus' analysis, Integragen (XPAR:ALINT) is currently considered Possible Value Trap. The stock's GF Value™ is €0.42, compared to a current price of €0.17 — trading 59.4% below its estimated fair value. The current Total Receivables is €1.40 Mil. Integragen's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Integragen (XPAR:ALINT), the current Total Receivables is €1.40 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integragen (XPAR:ALINT) Overvalued in 2026?

Based on GuruFocus' analysis, Integragen stock appears to be undervalued. The current stock price of €0.17 is trading 59.4% below its estimated GF Value™ of €0.42. GuruFocus considers Integragen to be Possible Value Trap.

Key valuation signals for XPAR:ALINT:

  • Total Receivables: €1.40 Mil
  • GF Value™: €0.42 vs. price of €0.17 (59.4% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integragen Business Description

Other Exchanges 7N8:Germany
Address Genopole Campus 1 - Genavenir, 85 rue Henri Desbrueres, Evry, FRA, 91000
Integragen is engaged in the development of genetic biomarkers. It offers genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, as well as genomic research tools and solutions to microbiologic researchers.
36GF Score

Get the complete analysis for XPAR:ALINT

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price
€0.42
GF Value